NOT KNOWN FACTUAL STATEMENTS ABOUT HEMGENIX

Range of qualified patients: CDEC talked over the uncertainty in the amount of patients with moderately severe to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some individuals who will be categorized as getting moderate or reasonable disease may have a critical bleeding